menu
    • menu
    [{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Not Applicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ National Cancer Institute"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SN BioScience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for 7-Ethyl-10-Hydroxycamptothecin

    Menu

    7-Ethyl-10-Hydroxycamptothecin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SN BioScience

                            South Korea arrow
                            PackExpo
                            Not Confirmed

                            SN BioScience

                            South Korea arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Grants Orphan Drug Designation for SNB-101 for Small Cell Lung Cancer

                            Details : SNB-101 (SN-38) is a first nanoparticle formulation of the anticancer drug SN-38. SN-38 is an active metabolite of Irinotecan, being evaluated for the treatment of small cell lung cancer.

                            Brand Name : SNB-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ProLynx

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ProLynx Announces Initiation Of Phase II Clinical Trial Of Its DNA-Damaging Agent PLX038 in Patients With Plat...

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Brand Name : PLX038

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 07, 2022

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ProLynx

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38)

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Brand Name : PLX038

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 13, 2020

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth